A Phase II Study of Paclitaxel+S-1 for previously treated Non-Small Cell Lung Cancer

A Phase II Study of Paclitaxel+S-1 for previously treated Non-Small Cell Lung Cancer - A Phase II Study of Paclitaxel+S-1 for previously treated Non-Small Cell Lung Cancer

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000003719

Enrollment

Registered

2010-06-06

Start date

2009-07-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Advanced or relapsed Non-Small Cell Lung Cancer

Interventions

Paclitaxel + S-1

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1)Histologically confirmed Non-Small Cell Lung Cancer 2)Advanced Stage (IV or IIIB) 3)With measurable lesion 4)One more prior platinum-based chemotherapy 5)The case of prior Paclitaxel or S-1 treatment is accceptable. 6)20<=, <75 years 7)Performance Status(ECOG):0-1 8)Oral intake is possible 9)Adequate organ functions 10)Patients who have estimated life expectancy longer than 3 months 11)Written informed consent

Exclusion criteria

Exclusion criteria: 1)uncontrollablenangina pectoris, arrythmia or heart failure 2)Hystory of active double cancer 3)complication of superior vena cava syndrome 4)complication ofliver cirrhosis 5)Interstitial pneumonaitis on chest x-ray 6)complication ofgastrointestinal bleeding 7)poorly controled diabetes mellitus 8)symptoms of ileus or watery diarrhea 9)Patients with serious infections or susupected infections with fever 10)complication of massive pericardial effusion, ascites or pleural sffusion 11)Pregnant or lactating woman 12)Symptomatic brain metastasis 13)Patients whose participation in the trial is judged to be inappropriate by the attending doctor.

Design outcomes

Primary

Measure	Time frame
Response rate	—

Secondary

Measure	Time frame
Progression free survival 1-year suvival rate safety	—

Countries

Japan

Contacts

Public ContactKazumi Nishino

Osaka Medical Center for Cancer and Cardiovascular Diseases Pulmonary Oncology

nisino-ka@mc.pref.osaka.jp06-6972-1181

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026